Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Measovir is a live attenuated measles vaccine developed and manufactured by the Serum Institute of India. It contains the Edmonston-Zagreb strain of the measles virus, which has been attenuated through serial passage in human diploid cells. The vaccine is indicated for the active immunization of children and adults against measles. Upon administration, the attenuated virus replicates minimally, mimicking a natural infection to elicit a robust and long-lasting immune response, including the production of IgG antibodies and the activation of T-lymphocytes. It is typically supplied as a lyophilized powder that must be reconstituted with a sterile diluent before subcutaneous injection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on measles vaccine (live attenuated).